| Mar 18 2025 |
Trending in Telehealth: February 2025 |
McDermott Will & Emery |
| Mar 18 2025 |
GRAS Self-Affirmation for Food Ingredients – To Be or Not to Be? |
Beveridge & Diamond PC |
| Mar 18 2025 |
February 2025 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Mar 17 2025 |
Florida DABT Issues Declaratory Statement on Taxability of "Heat Stick" Products. |
Jones Walker LLP |
| Mar 17 2025 |
The Next Wave of ADA Website Accessibility Lawsuits Against Alcohol Suppliers |
McDermott Will & Emery |
| Mar 17 2025 |
Council of the EU Agrees on Negotiating Mandate on Plants Obtained by New Genomic Techniques |
Bergeson & Campbell, P.C. |
| Mar 17 2025 |
Telehealth Companies and Social Media Influencers May Face New FDA Laws |
Foley & Lardner LLP |
| Mar 17 2025 |
HHS Secretary Kennedy Directs FDA to Explore Rulemaking to Eliminate Self-Affirmed GRAS Pathway |
Keller and Heckman LLP |
| Mar 14 2025 |
Alert: New Mexico Is a Step Closer to Legalizing the Supervised Use of Psilocybin |
Womble Bond Dickinson (US) LLP |
| Mar 14 2025 |
Essential Employee Handbook Considerations for Florida Employers in 2025 |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Mar 14 2025 |
McDermott+ Check-Up: March 14, 2025 |
McDermott Will & Emery |
| Mar 14 2025 |
Judge Connolly (D. Del.) Overturns $96 Million Molecular Diagnostics Jury Verdict, Finds Patents Invalid Under § 112 |
Polsinelli PC |
| Mar 13 2025 |
FDA’s Backup LDT Enforcement Method: Specimen Collection Kits |
Mintz |
| Mar 13 2025 |
Skin360 App Can’t Escape Scrutiny under Illinois Biometric Law |
Robinson & Cole LLP |
| Mar 13 2025 |
Inventor’s Motivation to Combine Does Not Control Obviousness |
McDermott Will & Emery |
| Mar 13 2025 |
This Week in 340B: March 4 – 10, 2025 |
McDermott Will & Emery |
| Mar 12 2025 |
HHS Secretary Kennedy Directs FDA to Consider Eliminating Self-GRAS Determinations |
Keller and Heckman LLP |
| Mar 12 2025 |
Federal Circuit Affirms ImmunoGen Patent Obviousness |
ArentFox Schiff LLP |
| Mar 12 2025 |
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals |
Foley & Lardner LLP |
| Mar 12 2025 |
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs |
Foley & Lardner LLP |
| Mar 12 2025 |
Georgia Legislature Considering Substantial Overhaul to Medical Marijuana, Hemp Laws |
Bradley Arant Boult Cummings LLP |
| Mar 11 2025 |
Reminder: FDA Does, In Fact, Review DOF |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 11 2025 |
Federal Circuit Affirms District Court’s Obviousness Judgment on ImmunoGen Patent Application |
Polsinelli PC |
| Mar 11 2025 |
Leveraging USPTO Delays To Maximize Patent Term |
Foley & Lardner LLP |
| Mar 11 2025 |
SuperValu Wins False Claims Act Case with a “No Harm, No Foul” Jury Verdict |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 11 2025 |
Federal Appeals Court Rules Against Doctor Seeking to Use Mushrooms to Aide Terminal Patients: How We Learned to Question the Rationale of the Controlled Substances Act |
Bradley Arant Boult Cummings LLP |
| Mar 11 2025 |
EU Advocate General Recommends Overturning Decision Annulling Harmonized Classification and Labeling of Titanium Dioxide |
Bergeson & Campbell, P.C. |
| Mar 10 2025 |
Healthcare Preview for the Week of: March 10, 2025 [Podcast] |
McDermott Will & Emery |
| Mar 10 2025 |
Appellate Court Paves Way for Launch of Alabama Medical Cannabis Program: Watch What Happens Now |
Bradley Arant Boult Cummings LLP |
| Mar 9 2025 |
FDA Issues FSVP-Related Warning Letters |
Keller and Heckman LLP |
| Mar 7 2025 |
EPA Will Extend Deadline for Reporting Health and Safety Data for 16 Chemicals |
Bergeson & Campbell, P.C. |
| Mar 6 2025 |
First Circuit Adopts But-For Causation Standard for Kickback-Premised False Claims Act Actions |
K&L Gates LLP |
| Mar 5 2025 |
HHS Reverses Its Longstanding Policy and Limits Public Participation in Rulemaking |
Epstein Becker & Green, P.C. |
| Mar 5 2025 |
First Circuit Joins Other Circuits in Adopting Stricter Causation Standard in FCA Cases Based on Anti-Kickback Statute |
Bradley Arant Boult Cummings LLP |
| Mar 5 2025 |
Federal Circuit Refuses to Rehear Case Involving Orange Book Listing of Device Patents |
Polsinelli PC |
